Key result
Methanolic extract of jatamansi significantly reduced serum CK-MB, LDH, HMG-CoA, and tissue MDA levels (p < 0.001) in doxorubicin-treated rats, protecting against oxidative stress-induced injury.
Why the study?
The study was conducted to investigate the protective action of jatamansi (Nardostachys jatamansi DC.) against doxorubicin cardiotoxicity.
Does methanolic extract of jatamansi prevent doxorubicin-induced cardiotoxicity in Wistar rats?
Does methanolic extract of jatamansi prevent doxorubicin-induced cardiotoxicity in Wistar rats?
p-value: p=<0.001
Methanolic extract of jatamansi demonstrates protective effects against doxorubicin-induced cardiotoxicity in a rat model by reducing oxidative stress and lipid peroxidation.
Should not change doxorubicin cardioprotection practice; hypothesis-generating for jatamansi in oxidative cardiac injury models.
The study aimed to investigate the protective action of jatamansi (Nardostachys jatamansi DC.) against doxorubicin cardiotoxicity. Methanolic extract of jatamansi (MEJ) was prepared and standardized using HPTLC fingerprinting, GC-MS chemoprofiling, total phenolic content, and antioxidant activity in vitro. Further in vivo activity was evaluated using rodent model. Animals were divided into five groups (n = 6) namely control (CNT) (Normal saline), toxicant (TOX, without any treatment), MEJ at low dose (JAT1), MEJ at high dose (JAT2), and standard desferrioxamine (STD). All groups except control received doxorubicin 2.5 mg per Kg intra-peritoneally for 3 weeks in twice a week regimen. After 3 weeks, the blood samples and cardiac tissues were collected from all groups for biochemical and histopathological evaluation. Treatment with MEJ at both dose levels exhibited significant reduction (p < 0.001 vs. toxicant) of serum CK-MB (heart creatine kinase), LDH (Lactate dehydrogenase) & HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) levels, and tissue MDA (melondialdehyde) level; insignificant difference was observed (p > 0.05) in TNF-alpha (tumour necrosis factor), IL-6 (interleukine-6) levels and caspase activity as compared to TOX. Histopathological evaluation of cardiac tissues of different treatment groups further reinforced the findings of biochemical estimation. This study concludes that jatamansi can protect cardiac tissues from oxidative stress-induced cell injury and lipid peroxidation as well as against inflammatory and apoptotic effects on cardiac tissues.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2020) studied Doxorubicin cardiotoxicity (n=30). Methanolic extract of jatamansi (MEJ) vs. Toxicant (doxorubicin without treatment) was evaluated on Serum CK-MB, LDH, HMG-CoA, and tissue MDA levels (p=<0.001). Methanolic extract of jatamansi significantly reduced serum CK-MB, LDH, HMG-CoA, and tissue MDA levels (p < 0.001) in doxorubicin-treated rats, protecting against oxidative stress-induced injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: